4-HO-MiPT (miprocin) is not named in the DEA's August 2026 lists, but the Federal Analogue Act can still reach an unlisted psilocin analogue intended for human use.
4-HO-MiPT is not scheduled by name in the August 2026 federal lists of controlled substances, but it is not necessarily legal to buy, sell, or possess for human use. The Drug Enforcement Administration (DEA) explains that an unlisted chemical can still be treated as a controlled substance under federal law, specifically through the Federal Analogue Act when intended for human consumption. Whether a specific case involving 4-HO-MiPT satisfies those statutory criteria is decided case by case in court.
At The Psychedelic Journal, we reviewed the DEA controlled substance lists and published papers on October 18, 2026, to clarify where 4-HO-MiPT stands under federal law. 4-HO-MiPT, also known as miprocin or 4-hydroxy-N-methyl-N-isopropyltryptamine, is a tryptamine structurally related to psilocin. This page represents a desk review of published legal documents and scientific papers, and no human clinical trials appear in the sources reviewed.
4-HO-MiPT is not named on federal controlled substance schedules, but that absence from official lists does not establish that it is legal to manufacture, distribute, or possess. In the August 2026 edition of the DEA Diversion Control Division publication titled Lists of: Scheduling Actions, Controlled Substances, Regulated Chemicals, known as the Orange Book, 4-HO-MiPT does not appear anywhere in the schedules. A search of that publication confirms that neither miprocin nor the systematic name 4-hydroxy-N-methyl-N-isopropyltryptamine is listed. In contrast, psilocybin (drug code 7437) and psilocyn, also spelled psilocin (drug code 7438), are classified as Schedule I controlled substances.
The DEA provides an explicit warning in the foreword of its August 2026 lists regarding chemicals that do not appear by name. The agency explains that its published lists describe basic or parent chemicals and do not comprehensively cover every salt, isomer, ester, ether, or derivative that might be controlled under federal statutes. The agency states directly that a substance need not be listed as a controlled substance to be treated as a scheduled substance for criminal prosecution. The lists alone therefore support neither a claim that 4-HO-MiPT is legal nor a claim that it is an explicitly listed Schedule I drug.
Individuals or organizations seeking formal confirmation of a compound's regulatory standing can request agency clarification. The DEA foreword notes that outside parties who want to ensure that a compound is not considered a scheduled substance or listed chemical should write to the DEA Drug and Chemical Evaluation Section, Diversion Control Division, for an official determination. This publication has not requested or received any such administrative determination for 4-HO-MiPT. To understand how federal law classifies other psychedelic compounds, you can read our guide on what psychedelics are legal in the US.
Federal prosecutors can regulate unlisted chemicals using the Federal Analogue Act. According to the foreword of the DEA Orange Book, a controlled substance analogue is an unlisted substance intended for human consumption that meets specific statutory requirements. The foreword outlines these elements: the compound must be intended for human consumption, structurally substantially similar to a Schedule I or Schedule II substance, pharmacologically substantially similar to one or represented as being similar, and not an approved medication in the United States.
The statutory definition of a controlled substance analogue is codified at 21 U.S.C. § 802(32)(A), and the DEA foreword points to 21 U.S.C. § 813. Whether any individual prosecution meets the statutory definition is determined case by case in federal court.
We found no published court ruling, published DEA determination, or binding judicial precedent deciding whether 4-HO-MiPT meets the statutory definition of an analogue under federal law. In our guide to 4-AcO-DMT, we note that 4-AcO-DMT is also unlisted on federal schedules, but federal prosecutors have pursued cases under the Federal Analogue Act alleging that it serves as an analogue to psilocin. That history illustrates how federal prosecutors employ the statute, but it does not represent a formal legal finding regarding 4-HO-MiPT.
4-HO-MiPT is a tryptamine chemically designated as 4-hydroxy-N-isopropyl-N-methyltryptamine or 4-hydroxy-N-methyl-N-isopropyltryptamine. It carries a hydroxy group attached at the 4-position of the indole ring, which is the exact substitution position found on psilocin (4-hydroxy-N,N-dimethyltryptamine).
The primary structural distinction between 4-HO-MiPT and psilocin sits on the terminal nitrogen atom of the side chain. While psilocin carries two methyl groups on that nitrogen atom, 4-HO-MiPT carries one methyl group and one isopropyl group. The compound is also identified by the name miprocin; for example, a 2020 scientific paper titled Bis(4-hydroxy-N-isopropyl-N-methyl-tryptammonium) fumarate: a new crystalline form of miprocin identifies the substance directly as 4-HO-MiPT.
Solid-state characteristics of the compound were characterized in two academic papers published in Acta Crystallographica Section E. A 2019 study and a 2020 study by Chadeayne and colleagues examined the crystal structures of 4-HO-MiPT fumarate salts. The authors, affiliated with CaaMTech, LLC and the University of Massachusetts Dartmouth, evaluated hydrogen bonding and side-chain disorder in the crystals. Neither publication examined pharmacological activity or reported effects on animals or humans.
Published laboratory and animal research from 2026 provides empirical data on the receptor pharmacology and behavioral profile of 4-HO-MiPT. In a 2026 study published in ACS Chemical Neuroscience, Glatfelter and colleagues, including investigators from the National Institute on Drug Abuse (NIDA) Intramural Research Program, evaluated 4-MeO-MiPT, its 4-hydroxy derivative 4-HO-MiPT, and related compounds. In in vitro receptor assays, the tested compounds displayed agonist activity at serotonin receptors, including 5-HT2A receptor agonism with EC50 values between 10 and 118 nM. The 4-hydroxy compounds were less potent than their 4-methoxy counterparts at inhibiting the serotonin transporter (SERT), exhibiting IC50 values ranging from 280 to 423 nM.
The same 2026 investigation examined behavioral responses in mice following subcutaneous administration of doses ranging from 0.03 to 30 mg/kg. 4-HO-MiPT and 4-MeO-MiPT showed similar potencies for inducing the head-twitch response, a mouse behavior used as a model of psychedelic-like effect, with ED50 values of 0.75 mg/kg and 0.97 mg/kg respectively. However, 4-MeO-MiPT induced fewer total head twitches at its maximal effect. Pretreatment of mice with the SERT inhibitor fluoxetine at 10 mg/kg reduced the maximal head-twitch frequency induced by 4-HO-MiPT. Mouse experimental doses cannot be converted or applied to human consumption.
A separate 2026 study by Lovell and colleagues published in the Journal of Psychopharmacology examined psilocybin derivatives in mice using a fentanyl-induced conditioned place preference model. Psilocin reduced fentanyl preference in female mice but not in male mice, while 4-MeO-MiPT reduced preference across both sexes. In contrast, 4-HO-MiPT produced no change in fentanyl place preference in either sex. In elevated plus maze testing, none of the tested substances significantly altered anxiety-like behaviors. The investigators' conclusion supports further preclinical work on psilocin and 4-MeO-MiPT, not on 4-HO-MiPT. No human clinical trials appear in the reviewed literature.
4-HO-MiPT shares a chemical framework with psilocin. Psilocin is 4-hydroxy-N,N-dimethyltryptamine, listed alongside psilocybin on federal Schedule I. The 2019 Chadeayne paper explicitly describes 4-HO-MiPT as the N-isopropyl-N-methyl derivative of psilocin, pointing directly to the modification on the amine nitrogen.
Other variations exist within this chemical class, such as 4-HO-MET (metocin), a different psilocin analogue. While both 4-HO-MiPT and 4-HO-MET are 4-hydroxy tryptamine derivatives, nothing in the scientific or legal literature reviewed indicates that they are legally or pharmacologically identical.
From a federal scheduling standpoint, psilocin remains an explicitly listed Schedule I substance, whereas 4-HO-MiPT does not appear by name in the August 2026 DEA lists. For a wider review of federal classifications across psychedelics, see our guide on legal psychedelics in the US.
State controlled substance legislation operates independently of the federal lists published by the DEA. Individual states maintain their own statutory schedules, and state drug laws vary. Consequently, absence from the federal Orange Book does not mean a chemical is unscheduled under state criminal codes.
We make no state-by-state claims regarding the legal status of 4-HO-MiPT, because we have not verified state statutes for this specific chemical. State-level treatment of related tryptamines cannot be assumed to apply to 4-HO-MiPT. For instance, our 4-AcO-DMT guide reports that Florida, Georgia and Louisiana explicitly schedule 4-AcO-DMT, but that does not show those states have scheduled 4-HO-MiPT.
To track state-level statutory updates regarding naturally occurring psychedelics, readers can review our legal status by state guide and our psychedelic legal map.
Published research on 4-HO-MiPT leaves major informational gaps. The pharmacological literature reviewed here consists of crystal-structure papers, laboratory receptor tests and mouse studies, and no human clinical trial appears in the sources reviewed. This page provides no dose guidelines, no preparation or manufacturing instructions, and no sourcing information.
Regulatory status also requires caution. The DEA explains in its Orange Book foreword that outside parties seeking to confirm that a substance is not treated as a scheduled drug should submit a written request to the DEA Drug and Chemical Evaluation Section, Diversion Control Division. A qualified attorney can evaluate how federal analogue provisions or local statutes apply to 4-HO-MiPT in a specific legal situation.
4-HO-MiPT is not listed by name in federal controlled substance schedules, but that omission does not confirm that it is legal to manufacture, sell, or possess. Under the Federal Analogue Act, an unlisted chemical intended for human consumption can be treated as a Schedule I substance if it meets statutory similarity tests. Whether 4-HO-MiPT satisfies that legal standard in a specific case is decided in court.
Yes, miprocin is an alternate common name for 4-HO-MiPT. Published scientific literature, including crystallographic studies, identifies miprocin as 4-hydroxy-N-isopropyl-N-methyltryptamine. Both names describe the identical chemical compound.
4-HO-MiPT is not named as a Schedule I controlled substance in the August 2026 DEA Orange Book. However, the DEA foreword notes that a substance does not need to be listed to be treated as a controlled substance for criminal prosecution. Federal prosecutors can treat unlisted substances as Schedule I drugs if they meet the criteria of the Federal Analogue Act.
4-HO-MiPT is the N-isopropyl-N-methyl derivative of psilocin, meaning it differs at the terminal amine nitrogen. Psilocin carries two methyl groups at that position, whereas 4-HO-MiPT carries one methyl group and one isopropyl group. Legally, psilocin is an explicitly listed federal Schedule I controlled substance, while 4-HO-MiPT is not listed by name.
No human clinical trials of 4-HO-MiPT appear in the scientific sources reviewed for this page. The available peer-reviewed literature consists of solid-state crystallography, laboratory receptor tests, and laboratory mouse experiments.
We have not verified state statutes for 4-HO-MiPT, and this page makes no claims regarding state-level legality. State controlled substance laws function independently from federal schedules and vary by state. An attorney can advise on specific state laws.
Get psilocybin research & policy updates
New trials, FDA decisions, and legal changes for psilocybin — delivered when they happen.
Suggest a tool, topic, or improvement that would make this site more useful.